Vietnam tuberculosis therapeutics market
is anticipated to register growth with an impressive CAGR in the forecast
period, 2023-2027, on the account of growing demands for the effective
treatment and efficient pharmaceuticals to control the growing instances of
tuberculosis among the population. Increasing investments and grants for the
tuberculosis therapeutics in the country further drive the growth of the
Vietnam tuberculosis therapeutics market in the upcoming five years. Tuberculosis
has been a major cause of death in the country in past years. The government is
actively taking initiatives and schemes like National Tuberculosis Control
Programme (NTP) to control the cases. Government initiatives and rising
awareness about the communicable disease is further supporting the growth of
the Vietnam tuberculosis therapeutics market in the next five years.
High Prevalence of Tuberculosis Drives
Market Growth
Although multiple initiatives and
therapeutic treatments are available, the instances of tuberculosis are still
high and actively driving the growth of the Vietnam tuberculosis therapeutics
market in the upcoming five years. In the year 2020, 176 in 100,000 people in
the country were actively infected with tuberculosis. Moreover, the death count
due to tuberculosis was also registered to be 8.9 cases per 100,000 in the year
2020, that created urgency for better and efficient treatments and precautions
thereby supporting the growth of the Vietnam tuberculosis therapeutics market
in the next five years.
Communicable diseases and infectious
diseases are a severe threat in the South-Asian countries. Long period of lack
in advanced medicine and lack of awareness among the population regarding
maintaining standards of hygiene further aided to increasing cases of the
infectious communicable diseases. Vietnam is committed to reduce the instances
of tuberculosis to 20 per 100,000 by the end of 2030 under the functioning of
National Tuberculosis Control Programme (NTP). Commitments toward overcoming
the diseases further facilitates the growth of the Vietnam tuberculosis
therapeutics market in the future five years.
Investments & Privatized Healthcare
System Facilitate Market Growth
Population in the country is seen to
shift toward private healthcare systems for the therapeutics and treatment for
various communicable and infectious diseases, owing to the flexible diagnostic
procedures, drug regimes, and treatment observation methods. Recent studies
prove that majority of the population in the country still go unnoticed for the
tuberculosis cases and in such conditions private healthcare systems play vital
role in the early diagnostics and provision of advanced medical attention,
thereby aiding the market growth.
The Ministry of Health of Vietnam passed
law in the year 2013 that enabled systematic inclusions of private healthcare
providers that were not included in the National Tuberculosis Control Programme
to facilitate better healthcare services for the TB patients in the country. Further
investments and support to overcome the TB cases is carried out through the US
President’s Emergency Plans for AIDS Relief (PEPFAR). The scheme actively
invests in the NTP thus granting funds for the expansion and advancement of the
healthcare infrastructure in the country.
Click here to download the sample
Market Segmentation
The Vietnam tuberculosis
therapeutics market is segmented by diseases type, therapy, competitional
landscape, and regional distribution. Based
on disease type, the market is bifurcated between active tuberculosis and
latent tuberculosis. Based on therapy, the market is differentiated between
first line therapy and second line therapy. The market analysis also studies
the regional segmentation to devise regional market segmentation, divided among
Northern Region, Central region, and the Southern Region.
Company Profile
Novartis Vietnam Co., Ltd., Johnson
& Johnson, Otsuka Pharmaceutical Vietnam JSC, Lupin Limited, GSK Vietnam, among others is a partial list of
major market players of the companies responsible for the growth of Vietnam tuberculosis
therapeutics market.
|
Attribute
|
Details
|
|
Base Year
|
2021
|
|
Historical Data
|
2017 –
2020
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023
– 2027
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
|
|
Report coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments covered
|
|
|
Regional scope
|
Northern Region, Central Region, and Southern Region.
|
|
Key companies profiled
|
Novartis Vietnam Co., Ltd., Johnson & Johnson, Otsuka Pharmaceutical
Vietnam JSC, Lupin Limited, GSK Vietnam
|
|
Customization scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email (We can also
provide the editable version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, Vietnam tuberculosis therapeutics market has been segmented into
following categories, in addition to the industry trends which have also been
detailed below:
- Vietnam Tuberculosis Therapeutics Market,
By Disease Type:
- Active Tuberculosis
- Latent Tuberculosis
- Vietnam Tuberculosis Therapeutics Market,
By Therapy:
- First Line Therapy
- Second Line Therapy
- Vietnam Tuberculosis therapeutics Market,
By Region:
o Northern Region
o Central Region
o Southern Region
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in Vietnam tuberculosis therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
Vietnam Tuberculosis Therapeutics
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]